Literature DB >> 16157741

Characterizing the mechanisms of progression in multiple sclerosis: evidence and new hypotheses for future directions.

E M Frohman1, M Filippi, O Stuve, S G Waxman, J Corboy, J T Phillips, C Lucchinetti, J Wilken, N Karandikar, B Hemmer, N Monson, J De Keyser, H Hartung, L Steinman, J R Oksenberg, B A C Cree, S Hauser, M K Racke.   

Abstract

Major advancements have been achieved in our ability to diagnose multiple sclerosis (MS) and to commence treatment intervention with agents that can favorably affect the disease course. Although MS exacerbations and the emergence of disability constitute the more conspicuous aspects of the disease process, evidence has confirmed that most of the disease occurs on a constitutive and occult basis. Disease-modifying therapies appear to be modest in the magnitude of their treatment effects, particularly in the progressive stage of the disease. Therapeutic strategies currently used for MS primarily target the inflammatory cascade. Several potential mechanisms appear to be involved in the progression of MS. Characterizing these mechanisms will result in a better understanding of the various forms of the disorder and how to effectively treat its clinical manifestations. It is our objective within this 2-part series on progression in MS to offer both evidence-based observations and hypothesis-driven expert perspectives on what constitutes the cause of progression in MS. We have chosen areas of inquiry that appear to have been most productive in helping us to better conceptualize the landscape of what MS looks like pathologically, immunologically, neuroscientifically, radiographically, and genetically. We have attempted to advance hypotheses focused on a deeper understanding of what contributes to the progression of this illness and to illustrate new technical capabilities that are catalyzing novel research initiatives targeted at achieving a more complete understanding of progression in MS.

Entities:  

Mesh:

Year:  2005        PMID: 16157741     DOI: 10.1001/archneur.62.9.1345

Source DB:  PubMed          Journal:  Arch Neurol        ISSN: 0003-9942


  28 in total

1.  A one-year prospective, randomized, placebo-controlled, quadruple-blinded, phase II safety pilot trial of combination therapy with interferon beta-1a and mycophenolate mofetil in early relapsing-remitting multiple sclerosis (TIME MS).

Authors:  Gina M Remington; Katherine Treadaway; Teresa Frohman; Amber Salter; Olaf Stüve; Michael K Racke; Kathleen Hawker; Federica Agosta; Maria Pia Sormani; Massimo Filippi; Elliot M Frohman
Journal:  Ther Adv Neurol Disord       Date:  2010-01       Impact factor: 6.570

Review 2.  Optical coherence tomography: a window into the mechanisms of multiple sclerosis.

Authors:  Elliot M Frohman; James G Fujimoto; Teresa C Frohman; Peter A Calabresi; Gary Cutter; Laura J Balcer
Journal:  Nat Clin Pract Neurol       Date:  2008-12

Review 3.  Pharmacological Approaches to the Management of Secondary Progressive Multiple Sclerosis.

Authors:  A Nandoskar; J Raffel; A S Scalfari; T Friede; R S Nicholas
Journal:  Drugs       Date:  2017-05       Impact factor: 9.546

4.  β2-adrenergic receptor and astrocyte glucose metabolism.

Authors:  Jun-hong Dong; Xin Chen; Min Cui; Xiao Yu; Qi Pang; Jin-peng Sun
Journal:  J Mol Neurosci       Date:  2012-03-08       Impact factor: 3.444

5.  MR imaging intensity modeling of damage and repair in multiple sclerosis: relationship of short-term lesion recovery to progression and disability.

Authors:  D S Meier; H L Weiner; C R G Guttmann
Journal:  AJNR Am J Neuroradiol       Date:  2007 Nov-Dec       Impact factor: 3.825

Review 6.  Mechanisms of action of ACTH in the management of relapsing forms of multiple sclerosis.

Authors:  Regina Berkovich; Mark A Agius
Journal:  Ther Adv Neurol Disord       Date:  2014-03       Impact factor: 6.570

7.  Immunopathogenesis of multiple sclerosis.

Authors:  Michael K Racke
Journal:  Ann Indian Acad Neurol       Date:  2009-10       Impact factor: 1.383

8.  The role of infections in the pathogenesis and course of multiple sclerosis.

Authors:  Siddharama Pawate; Subramaniam Sriram
Journal:  Ann Indian Acad Neurol       Date:  2010-04       Impact factor: 1.383

9.  Expansion of CD27high plasmablasts in transverse myelitis patients that utilize VH4 and JH6 genes and undergo extensive somatic hypermutation.

Authors:  A J Ligocki; W H Rounds; E M Cameron; C T Harp; E M Frohman; A M Courtney; S Vernino; L G Cowell; B Greenberg; N L Monson
Journal:  Genes Immun       Date:  2013-04-18       Impact factor: 2.676

Review 10.  Corticosteroids for multiple sclerosis: II. Application for disease-modifying effects.

Authors:  Anjali Shah; Eric Eggenberger; Robert Zivadinov; Olaf Stüve; Elliot M Frohman
Journal:  Neurotherapeutics       Date:  2007-10       Impact factor: 7.620

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.